Background: A 2019 study by Prucnal and colleagues found that the majority of patients
treated with unfractionated heparin for pulmonary embolism did not maintain therapeutic …

Background: Anticoagulation in patients with pulmonary embolism. Objective: To identify
how non-vitamin K antagonist oral anticoagulants are associated with multiple outcomes in …

Each year nearly one million patients in the US and Europe are affected by Pulmonary
Embolism (PE), a blood clot causing a blockage in one or more pulmonary arteries within …

Background The pathophysiology of chronic thromboembolic pulmonary hypertension
(CTEPH) is not fully understood. Poor-quality anticoagulation may contribute to a higher risk …

Background The use of thrombolysis in patients with acute, intermediate-risk pulmonary
embolism (PE) remains controversial. This meta-analysis compared the efficacy and safety …

Introduction Anticoagulant treatment reduces recurrent venous thromboembolism (VTE) by
about 90% after index pulmonary embolism. Whether anticoagulant treatment also reduces …

Apixaban Length-Of-Stay Pulmonary Embolism study - Hospital Admissions (ALPHA-PE), Final
results Page 1 BSH 2020 Poster presented at: Apixaban Length-Of-Stay Pulmonary Embolism …

Anticoagulation (AC) is a sine qua non for the treatment of venous thromboembolism. The
addition of thrombolytics to AC is associated with more effective and efficient lysis of the …

Benefits and harms of long-term anticoagulant therapy (AT) after acute pulmonary embolism
(PE) are poorly known. The aim of this study was to investigate the outcome of patients with …

Background Pulmonary embolism (PE) is a life‐threatening disease where preemptive
anticoagulation is recommended by guidelines for patients with intermediate to high pretest …